Smith & Nephew Orthopaedics of Memphis, TN, announced last week that it has received premarket approval from the FDA to market its Exogen 2000, a noninvasive ultrasound fracture therapy, for the treatment of established nonunion bone fractures.The
Smith & Nephew Orthopaedics of Memphis, TN, announced last week that it has received premarket approval from the FDA to market its Exogen 2000, a noninvasive ultrasound fracture therapy, for the treatment of established nonunion bone fractures.
The FDA approved the Exogen device in 1994 as a treatment for the acceleration of fresh fracture healing. With this PMA, Exogen becomes the only bone stimulation treatment available for both fresh and nonunion fractures. Currently, the therapy has been prescribed for more than 18,000 patients in the U.S. by more than 7000 physicians.
A nonunion is considered to be established when a fracture is at least nine months old and has shown no progression of healing for at least three months. According to Smith & Nephew, their clinical studies for the PMA resulted in an 86% healed rate for nonunion fractures that failed to heal after prior orthopedic treatment. Exogens proprietary ultrasound and mechanical stress technologies are based on the principle that bone growth is stimulated by mechanical force.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.